AUMED, a.s. successfully completed the project “Comparison of the effectiveness of three different batches of leukocyte extract with transfer factor activity (TFI) in the form of fast-dissolving tablets”

AUMED, a.s. successfully completed the project “Comparison of the effectiveness of three different batches of leukocyte extract with transfer factor activity (TFI) in the form of fast-dissolving tablets”, registration number CZ.01.01.01/05/23_009/0001324.

The company AUMED, a.s. is engaged in the research and development of an immunomodulator based on transfer factors, which will be administered in the innovative form of a lyophilized tablet. The subject of the project “Comparison of the effectiveness of three different batches of leukocyte extract with transfer factor activity (TFI) in the form of fast-dissolving tablets” was the implementation of a project of experiments with the aim of comparing the biological effectiveness of three different batches of leukocyte extract with transfer factor activity (TFI) in the form of fast-dissolving tablets. The experimental project was designed on guinea pigs, in which a series of examinations was performed from the obtained blood samples. The results of the examination presented the changes in the immune system of the guinea pigs after administration of the product, and then a comparison of the effectiveness of three batches of the product, which were the subject of the trial project, was carried out.

The experiments performed showed that all three batches of TFI administered orally in the form of fast-dissolving tablets showed the same effectiveness.

The project received financial support from the EU within the Operational Program Technology and Applications for Competitiveness, Challenges Innovation vouchers – challenge II.